Bayer glucose meter aimed at gamers

Share this article:
Bayer glucose meter aimed at gamers
Bayer glucose meter aimed at gamers
Bayer Diabetes Care partnered with Nintendo on a glucose meter for kids that incorporates gaming.

Bayer's Didget meter plugs into the Nintendo DS and DS Lite handheld gaming systems, where kids can use points earned by consistent testing on unlocking levels in a game called Knock 'Em Downs: World's Fair. The meter, aimed at kids ages 4-14, will also connect to Bayer's password protected web community bayerdidget.com.

An extension of Bayer's Contour line of meters, it launched in the UK last summer and will retail in drug stores for a suggested price of $74.99.

The company is keeping quiet about its advertising plans – a spokeswoman would allow only that “We do have a robust promotional program planned.” Bayer, which recently consolidated its healthcare advertising into Omnicom and WPP, uses BBDO for consumer advertising and Cline, Davis & Mann for professional.

Contour USB meter user and Bayer diabetes “ambassador” Nick Jonas is, at 17, too old for the device, but was quoted in a release plugging the Didget as a “cool and fun way” for kids to test their blood sugar, and noting that it “uses the same test strips as the Contour meter, the strips I rely on every day.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...